

Ahmad Najem

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7482868/publications.pdf>

Version: 2024-02-01

15
papers

505
citations

840728

11
h-index

996954

15
g-index

16
all docs

16
docs citations

16
times ranked

1004
citing authors

#	ARTICLE	IF	CITATIONS
1	Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma. <i>Nature Cell Biology</i> , 2020, 22, 986-998.	10.3	148
2	PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies. <i>Cancers</i> , 2017, 9, 172.	3.7	91
3	p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib. <i>European Journal of Cancer</i> , 2016, 55, 98-110.	2.8	48
4	P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. <i>European Journal of Cancer</i> , 2017, 83, 154-165.	2.8	42
5	Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cells. <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 880-888.	5.5	28
6	New Drug Combination Strategies in Melanoma: Current Status and Future Directions New Drug Combination Strategies in Melanoma: Current Status and Future Directions. <i>Anticancer Research</i> , 2017, 37, 5941-5953.	1.1	27
7	RTK Inhibitors in Melanoma: From Bench to Bedside. <i>Cancers</i> , 2021, 13, 1685.	3.7	26
8	The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. <i>Cancers</i> , 2019, 11, 1093.	3.7	18
9	Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma. <i>Oncotarget</i> , 2018, 9, 31888-31903.	1.8	18
10	Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. <i>Cancers</i> , 2020, 12, 512.	3.7	15
11	Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis. <i>Cancers</i> , 2020, 12, 1323.	3.7	13
12	Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma. <i>Cells</i> , 2022, 11, 1157.	4.1	12
13	Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms. <i>Biology</i> , 2020, 9, 218.	2.8	9
14	Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value. <i>Frontiers in Oncology</i> , 2021, 11, 780654.	2.8	7
15	Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit. <i>Molecular Cancer Research</i> , 2021, 19, 1221-1233.	3.4	3